2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor system
2021
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trials
1992
Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimine
Sofuoglu M, Portoghese P, Takemori A. Maintenance of acute morphine tolerance in mice by selective blockage of κ opioid receptors with norbinaltorphimine. European Journal Of Pharmacology 1992, 210: 159-162. PMID: 1318206, DOI: 10.1016/0014-2999(92)90666-r.Peer-Reviewed Original ResearchConceptsMorphine injectionSelective kappa opioid antagonistED50 valuesKappa-opioid antagonistAcute morphine toleranceTail-flick assayDevelopment of toleranceKappa-opioid sitesAntinociceptive ED50 valueNon-pretreated controlsSupraspinal sitesOpioid toleranceMorphine administrationControl miceMorphine sulfateMorphine toleranceOpioid agonistsOpioid antagonistSpinal sitesSingle doseOpioid receptorsOpioid sitesMorphineMiceSelective blockage
1991
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.
Sofuoglu M, Portoghese P, Takemori A. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. Journal Of Pharmacology And Experimental Therapeutics 1991, 257: 676-80. PMID: 1851833.Peer-Reviewed Original ResearchConceptsAntinociceptive ED50Antinociceptive actionMorphine sulfateAntinociceptive assaysDelta-opioid receptor agonistDelta opioid receptor subtypesDelta-opioid subtypesOpioid receptor agonistsOpioid receptor subtypesSingle large doseDelta-opioid agonistsPretreatment of animalsOpioid subtypesOpioid agonistsSpinal sitesDifferential antagonismReceptor agonistReceptor subtypesAntinociceptive activityD-Ala2Large doseDSLETDPDPENaltrindoleAntagonist activity